ABSTRACT The somatic cell hybrid method has been used to study the number and different types of human genes involved in the expression of adenosine deaminase (ADA; adenosine aminohydrolase, EC 3.5.4.4) in normal cells and cells from a patient with ADA-deficient severe combined immunodeficiency disease (SCID). Genetic and biochemical characterization of ADA in SCID and the ADA tissue-specific isozymes in normal human cells indicates that additional genes, besides the ADA structural gene on chromosome 20, are involved in ADA expression. Human chromosome 6 encodes a gene, ADCP-1, whose presence is necessary for the expression of an ADAcomplexing protein in human-mouse somatic cell hybrids [Koch, G. & Shows, T. B. (1978) Proc. NatL Acad Sci. USA 75, 3876-38801. We report the identification of a second gene, ADCP-2, on human chromosome 2, that is also involved in the expression of the ADA-complexing protein. The data indicate that these two ADCPgenes must be present in the same cell for that cell to express the complexing protein. Human-mouse somatic cell hybrids, in which the human parental cells were fibroblasts from an individual with ADA-deficient SCID, also required human chromosomes 2 and 6 to express the ADAcomplexing protein, indicating that neither ADCP-1 nor ADCP-2 is involved in the ADA deficiency in SCID. The SCID-mouse hybrid cells expressed no human ADA even when human chromosome 20 had been retained. The deficiency of human ADA in these hybrids maps to human chromosome 20, and therefore is not due to the repression or inhibition of ADA or its product by unlinked genes or gene products. We propose that the expression of the polymeric ADA tissue isozymes in human cells requires at least three genes: ADA on chromosome 20, ADCP-1 on chromosome 6 , and AICP-2 on chromosome 2. A genetic scheme is presented and the different genes involved in ADA expression and their possible functions are discussed.
Adenosine deaminase (ADA; adenosine aminohydrolase, EC 3.5.4.4) catalyzes the hydrolytic deamination of adenosine to inosine during purine nucleotide salvage and consists of differentially expressed isozymes in human tissues. The genetic processes that result in (i) the generation of the tissue-specific ADA isozymes, whose expression reflects the signals of cellular differentiation (1) ; and (ii) the deficiency of ADA, which is associated with an autosomal recessive form of severe combined immunodeficiency disease (SCID) (2, 3) remain largely unresolved. The genetic dissection of these two aspects of human ADA expression, using somatic cell hybrids, is investigated here.
Human ADA consists of six different isozymes. The catalytic moiety of each of these isozymes is the product of the ADA locus on chromosome 20 (4), weighs 36,000 daltons (5), and is present as a monomer in erythrocytes and certain other tissues; this isozyme has been designated erythrocyte ADA, or ADA-I (1). The remaining five ADA tissue isozymes have molecular weights of t220,000 and are multimers of ADA-i and an ADA-complexing protein (6) (7) (8) . The ADA tissue isozymes are not present in erythroid cells; their presence requires the expression of human genes in addition to ADA (6) . The tissue specificity of these isozymes further suggests that more than one type of gene may be required for the appearance of these isozymes in human cells. We have described ADCP (adenosine deaminase complexing protein), on human chromosome 6, whose product is necessary for the expression of the ADA fibroblast isozyme, ADA-d, in somatic cell hybrids (6) . We showed that the ADCP gene product was involved in the conversion of ADA-I to ADA-d, in agreement with the biochemical evidence for the existence of an ADA-complexing protein in human kidney (8) and lung (9) . A second ADCP gene (10) is described here, which is encoded on human chromosome 2; its presence is also required for ADA-d expression in humanmouse somatic cell hybrids.
Identifying the type of genetic defect in SCID would provide information on the metabolic defect and whether different genes from those above are involved in ADA expression. Several genetic mechanisms have been proposed to explain the defect that results in ADA-deficient SCID, including control, inhibitor, and structural gene mutations (11) (12) (13) . It is possible to differentiate among these mechanisms and to determine the linkage relationships of genes that may be involved in ADA-deficient SCID by using cell hybrids formed between SCID fibroblasts and mouse cells. We have isolated such hybrids; the data indicate that the lack of ADA in ADA-deficient SCID is due either to the altered expression of, or a mutation in, the ADA locus on chromosome 20 . In either case, no human genes unlinked to ADA are involved in the ADA-deficient phenotype of primary SCID (14 (16) , DUV (17) , JoSt (18) , GM 194 (carrying an X/S translocation) (19) , GM 469 (ADA-deficient line established from a SCID patient) (20) , and GM 1006
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 (a mucolipidosis type II line) (21, 22) . Human leukocytes were from JoVa (23) and AlTr (24) . The fusions were performed by using either inactivated Sendai virus (25) or polyethylene glycol (26) . Interspecific cell hybrid clones were isolated and maintained as described (25) . The cell hybrids used in this study were from the independent hybrid sets: DUA (DUV-A9), DUM (DUV-RAG), ICL (6) (Fig. 1) . Two isozymes, ADA-1 and ADA-d, can occur in human fibroblast lines (1, 6, 27) . These two isozymes are present in various proportions, which depend on the tissue origin of the fibroblasts, culture conditions, and transformed state of the human cells (1, 27, 28) . In human-mouse somatic cell hybrid clones also, human ADA activity is expressed as ADA-1 and/or ADA-d (6) (Fig. 1 , channels 4-6). The structural gene for ADA-1 has been assigned to human chromosome 20 (4) ; when human chromosome 20 is not present in a hybrid clone, that clone expresses neither ADA-1 nor ADA-d (6), indicating that ADA-1 is required for the formation of ADA-d in hybrid cells, as it is in human cells (7, 29) . Extracts of ADA-deficient SCID tissues can convert exogenous ADA-1 to the appropriate tissue isozymes in vitro (7), a phenomenon that has been attributed to the presence of tissue-specific ADA-complexing proteins (8, 9 ) that spontaneously complex with ADA-1 to form the ADA tissue isozymes.
In a previous paper (6) , we demonstrated that ADA-complexing protein activity (recognized by the formation of ADA-d from ADA-1 in vivo, or from exogeneous ADA-i in vitro) was expressed in some human-mouse somatic cell hybrids. We observed that complexing protein activity was present if human chromosome 6 had been retained in the hybrid clones. Karyotypic analysis of 39 additional hybrid clones has confirmed the existence of an ADCP gene on human chromosome 6 and has shown that human chromosome 2 also contains a gene that is involved in the expression of the ADA-complexing protein ( Table 1 ). The data in Table 1 show that ADA-complexing protein activity is present in a human-mouse somatic cell hybrid clone only when human chromosomes 2 and 6 are present in the hybrid cells; if either of these two chromosomes has been lost in the clone, ADA-complexing protein activity is not expressed. Our previous results demonstrate that the presence of human chromosome 2 alone is not sufficient for ADA-complexing protein activity in human-mouse somatic cell hybrids (6) . When all other human chromosomes and enzyme markers for chromosomes were examined, no other pairs of human chromosomes concordantly segregated with the ADA-com- To define the genetic and molecular events that result in the expression of the ADA-complexing protein in hybrids con- _-_ 0 7 Trypsin/Giemsa banding was used to identify human metaphase chromosomes (23) . Replicate flasks of the hybrid clones were used for chromosome preparations and determinations of ADA-complexing protein activity. Numbers of clones with the indicated characteristics are tabulated. taiing human chromosomes 2 and 6, we examined the individual metaphases from each of the 19 ADCP+ hybrid clones and an additional three clones that appeared, through enzyme marker and chromosome analysis, to have retained both human chromosome 2 and chromosome 6, yet did not express the ADA-complexing protein. In each ADCP+ clone, at least 15% of the individual metaphases examined contained both chromosome 2 and chromosome 6; the three ADCP-2+ 6+ clones never retained both human chromosomes in the same cell. Furthermore Fig. 2 Lower: none of the SCID-RAG hybrids expressed human ADA, although all expressed mouse ADA. To determine if human chromosome 20, which contains the structural gene for ADA-1, had been retained in these hybrids, we analyzed the human ADA-hybrids for the syntenic marker (32) inosine triphosphatase (ITP). Nine of the hybrid clones contained a human-mouse ITP heteropolymer, demonstrating that human chromosome 20 had been retained in these human ADA-hybrids (Fig. 2 Upper). These human ITP+ ADA-clones also contained a structurally intact human chromosome 20 (Fig. 3) ; the hybrid from which the karyotype in Fig. 3 was derived contained at least one copy of chromosome 20 in 10 of the 16 A structurally intact human chromosome 20 has been retained in this hybrid clone (see Fig. 2 for the ADA and ITP phenotypes of this clone).
the ITP+ ADA-phenotype could be explained by the consistent loss or retention, respectively, of a syntenic group containing that gene. We therefore analyzed the nine ITP+ ADA-clones for human enzymes representing syntenic groups that have been assigned to each human chromosome. Human karyotypes were also prepared for three of these clones. The data from both the enzyme and chromosome analyses show that the absence of human ADA in the ITP+ ADA-hybrids could not be correlated with the presence or absence of any human linkage group, except those assigned to chromosome 20 and X (Table  2) . Because primary ADA-deficient SCID is inherited as an autosomal recessive phenotype, neither the human X nor the Y chromosome is involved in the human ADA deficiency. Therefore, the data indicate that the molecular defect resulting in the human ADA deficiency in these hybrids is encoded on human chromosome 20 alone, which chromosome contains the ADA structural gene. DISCUSSION We have used the somatic cell hybrid method to define genes designated ADCP-1 and ADCP-2 on human chromosomes 6 and 2, respectively, that are required for the presence of the ADA-complexing protein in human-mouse somatic cell hybrids. The individual products of these two genes do not interact in vitro to form a functional ADA-complexing protein; rather, the presence of ADCP-1 and ADCP-2 in the same cell is required for that cell to express the complexing protein.
The ADA-complexing protein assay was based on the established ability of the purified human protein to combine with ADA-1 to form the tissue isozyme ADA-d (8, 9) . The ADA-d in our hybrids that express both ADCP-1 and ADCP-2 has an G6PD   6  2  5  4  5  4  3  2  6  3  7  2  7  2  1  3  3  2  7  2  7  2  7  2  4  5  7  2  6  3  8  1  3  5  7  2  3  2  9   0   6  3  3  4  9   0 The human enzyme markers encoded on each human chromosome were all analyzed on the same homogenate to identify each linkage group (33, 34) . The + and -columns indicate, respectively, the number of ITP+ ADA-clones that had retained or lost the marker enzymes representative of each human linkage group. The chromosome assignments, gene symbols, and electrophoretic and visualization procedures have been described (33) (34) (35) . electrophoretic mobility that is identical to that found in human cells and tissues. We have examined the ADA phenotypes of mouse and human brain, liver, spleen, lung, colon, skeletal muscle, and heart. In the mouse, these diverse tissues all have ADA phenotypes identical to the phenotype of mouse erythrocyte ADA, whereas all of the corresponding human tissues contain unique ADA tissue isozyme patterns (1, 6, 7) . Extracts of the mouse tissues do not alter the mobility of either mouse or human erythrocyte ADA in vitro, whereas extracts of the human tissues convert exogenous human, but not mouse, erythrocyte ADA to the appropriate tissue isozymes. These results demonstrate that ADA-complexing proteins and electrophoretically discernible tissue isozymes are not present in mouse tissues. The presence of complexing protein activity in human-mouse somatic cell hybrids, therefore, must be due to the expression of a human gene(s) encoding an ADA-complexing protein. Thus, at least one of the two genes we have described is an ADCP structural gene.
The remaining ADCP gene probably serves one of three functions in human cells. The second ADCP gene might encode a second polypeptide subunit of the ADA-complexing protein, because the protein purified from human kidney is a glycoprotein dimer with subunits of similar, if not identical, molecular weights (8, 36, 37) . Alternatively, the second ADCP gene may function in the processing of the ADCP structural gene product. Biochemical evidence from the mucolipidoses suggests that the correct formation of ADA-d requires several genetically distinct processing steps of the ADA-complexing protein (38); one ADCP gene could then be involved in a step of this processing that is essential for ADA-complexing protein activity. Finally, the second ADCP gene could positively regulate the expression of the ADCP structural gene. That a genetic modulation of ADA-complexing protein activity occurs is demonstrated by the various levels of complexing protein activity in human tissues (1, 7, 9, 27) and by the decrease in cellular levels of ADA-d after simian virus 40 transformation (27) or lymphocyte stimulation (39) . A scheme of ADA tissue realization is shown in Fig. 4 .
Interspecific somatic cell hybrids between human fibroblasts derived from a SCID patient and mouse cells were constructed to characterize genetically the ADA deficiency in this disease. Each of the hybrid clones that retained human chromosomes 2 and 6 expressed the complexing protein as tested by the ability to convert exogenous ADA-1 to ADA-d. This observation demonstrates that the complexing protein is not implicated in ADA-deficient SCID, confirming the observations of Hirschhorn (7). Indeed, karyotypic and enzyme analysis of these hybrids demonstrated that only human chromosome 20, containing the ADA structural gene, can be implicated in the ADA deficiency in this SCID (Table 2) . Similar preliminary results obtained by using an obligate heterozygote for the ADA deficiency have been reported (40) .
Three mechanisms have been proposed for the lack of ADA activity that can occur in SCID: (i) the presence of an ADA inhibitor, resulting in reduced amounts of ADA activity (12) ; (fi) a defective modulation of the ADA structural gene, resulting in a decreased amount of ADA enzyme (11); and (iii) a mutation in the ADA structural gene itself, which yields a catalytically altered ADA (13). We have not observed an inhibition of mouse ADA activity in any of our SCID-RAG hybrids or a reappearance of human ADA in the SCID-RAG hybrids that had retained human chromosome 20. Our somatic cell hybrid data, therefore, indicate that the lack of ADA in ADA-deficient SCID is not caused by genes encoding an inhibitor of ADA activity or repressing the expression of ADA. Indeed, the residual ADA activity in SCID tissues and cultured fibroblasts exhibits an altered heat stability and electrophoretic mobility (13) . These observations are consistent with the interpretation that the altered ADA is encoded by an ADA gene carrying a mutation in the coding sequence for ADA-1, and are consistent with our results demonstrating that human ADA activity is not detectable on starch gels in SCID-RAG hybrids that have retained human chromosome 20 ( Table 2) . Because the catalytic moiety of ADA, ADA-1, is a monomer (1, 5, 40, 41) , it is not surprising (if ADA deficiency is due to a structural gene mutation) that the mouse genome does not complement the ADA deficiency of SCID in somatic cell hybrids to form an enzymatically active human-rodent heteropolymeric ADA. In summary, at least three human genes are required for the expression of the ADA tissue isozymes: ADA on chromosome 20, ADCP-1 on chromosome 6, and ADCP-2 on chromosome 2. The ADA deficiency in SCID segregates with chromosome 20 alone in interspecific somatic cell hybrids, suggesting that a structural gene mutation at the ADA locus is the primary cause of ADA-deficient SCID.
